bromocriptine prolactinoma
Selected indexed studies
- Diagnosis and Management of Pituitary Adenomas: A Review. (JAMA, 2023) [PMID:37097352]
- Treatment of Prolactinoma. (Medicina (Kaunas), 2022) [PMID:36013562]
- Pimozide augments bromocriptine lethality in prolactinoma cells and in a xenograft model via the STAT5/cyclin D1 and STAT5/Bcl‑xL signaling pathways. (Int J Mol Med, 2021) [PMID:33155660]
_Worker-drafted node — pending editorial review._
Connections
bromocriptine prolactinoma is a side effect of
Sources
- Treatment of Prolactinoma. (2022) pubmed
- Diagnosis and Management of Pituitary Adenomas: A Review. (2023) pubmed
- Pimozide augments bromocriptine lethality in prolactinoma cells and in a xenograft model via the STAT5/cyclin D1 and STAT5/Bcl‑xL signaling pathways. (2021) pubmed
- Tumor suppressor miR-145-5p sensitizes prolactinoma to bromocriptine by downregulating TPT1. (2019) pubmed
- Prolactinoma in pregnancy. (2011) pubmed
- Italian Guidelines for the Management of Prolactinomas. (2023) pubmed
- PGAM5-CypD pathway is involved in bromocriptine-induced RIP3/MLKL-dependent necroptosis of prolactinoma cells. (2019) pubmed
- Giant Prolactinomas. (2019) pubmed
- Bromocriptine and cabergoline induce cell death in prolactinoma cells via the ERK/EGR1 and AKT/mTOR pathway respectively. (2019) pubmed
- Curcumin Sensitizes Prolactinoma Cells to Bromocriptine by Activating the ERK/EGR1 and Inhibiting the AKT/GSK-3β Signaling Pathway In Vitro and In Vivo. (2021) pubmed